CMA
REGN icon

Cedar Mountain Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Cedar Mountain Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.7K Hold
22
– – ﹤0.01% 428
2026
Q1 		$17K Buy
+22
New +$16.8K ﹤0.01% 339

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Cedar Mountain Advisors's REGN Position: Q2 2026 in Review

Cedar Mountain Advisors held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2026 at 22 shares worth $13.7K. The position accounts for ﹤0.01% of the portfolio, ranked #428.

Cedar Mountain Advisors first reported a position in REGN in Q1 2026 and has held it in 2 quarters since. The position peaked at $17K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Cedar Mountain Advisors held 22 shares of Regeneron Pharmaceuticals worth $13.7K as of Q2 2026.
  • Cedar Mountain Advisors left its Regeneron Pharmaceuticals share count unchanged in Q2 2026.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Cedar Mountain Advisors's portfolio in Q2 2026, its #428 holding.
  • Cedar Mountain Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Cedar Mountain Advisors's Regeneron Pharmaceuticals position peaked at $17K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Cedar Mountain Advisors's 13F filing for Q2 2026, filed 2 Jul 2026.